{
    "id": "5c72bd047c78d69471000077",
    "question": "Can pazopanib be used for treatment von Hippel-Lindau disease?",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "A",
    "predict": "{\"step_by_step_thinking\": \"To answer this question, we need to consider the current medical literature and treatment guidelines for Hippel-Lindau disease (HL). HL is a genetic disorder characterized by the development of benign and malignant tumors in multiple organs, including the kidneys, spine, and retina. The treatment for HL typically involves surgical removal of tumors, as well as targeted therapy and surveillance. Pazopanib is a multi-targeted receptor tyrosine kinase inhibitor (RTKI) used primarily in the treatment of certain types of cancer, including renal cell carcinoma and soft tissue sarcoma. Given its mechanism of action, pazopanib has shown efficacy in inhibiting angiogenesis, which is a key process involved in the growth and progression of tumors. However, there is limited evidence to suggest that pazopanib has been specifically approved or studied for the treatment of HL. In fact, the current treatment guidelines for HL recommend a combination of surgery, chemotherapy, and targeted therapy, but pazopanib is not a standard treatment option. Furthermore, pazopanib has not been shown to have significant activity against the specific tumor types commonly associated with HL, such as hemangioblastomas. Therefore, based on the available evidence, pazopanib is not a recommended treatment for Hippel-Lindau disease.\", \"answer_choice\": \"B\"}",
    "snippets": [],
    "scores": [],
    "execution_time": 33.61971092224121
}